Back to search results

Comparing Magnesium Doses for Atrial Fibrillation or Flutter

This study is comparing two different doses of Magnesium Sulfate (2 grams and 4 grams) against a placebo (saline) to see which is most effective and safe for treating Atrial Fibrillation or Atrial Flutter with Rapid Ventricular Response (AFF RVR). AFF RVR is a condition where your heart beats too fast. The main goal is to see if these magnesium doses can help control your heart rate within the first two hours. You may be able to join if you are 18 or older, have a primary diagnosis of AFF RVR with a heart rate of 120 bpm or more, are taking diltiazem for rate control, and speak English. You cannot join if you have very low blood pressure, impaired consciousness, severe kidney disease, or acute heart failure. The current recruitment status is unclear.

Study design
This is a prospective, randomized, double-blinded study, meaning participants are assigned to a treatment group by chance, and neither you nor your doctors will know which treatment you are receiving. The study plans to enroll 153 participants.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
The primary outcome is measured within the first 2 hours of intravenous magnesium administration.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06376916

Comparing Magnesium 2g Versus 4g Versus Placebo in the Incidence of Treating AFF RVR

Recruiting
PHASE3Ages 18+InterventionalTreatment
Wake Forest University Health Sciences
~153 participants
Updated 2025-10-28 on ClinicalTrials.gov
What's tested:Magnesium Sulfate 2 GMagnesium Sulfate 4 GSaline

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Ventricular rate control
Measured over Within the first 2 hours of intravenous magnesium administration

Conditions

Tachycardia Atrial
Atrial Fibrillation
Atrial Flutter With Rapid Ventricular Response

Explore related trials

Atrial FibrillationAtrial Flutter

Where it's being run

1 sites across 1 states
Illinois1

Study leadership

  • Travis Hase, MD · PRINCIPAL_INVESTIGATOR · Wake Forest University Health Sciences

Who to contact

Marc McDowell, PharmD
[email protected]
(708) 684-1078
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Age \> 18 years or older
Able to provide informed consent
Primary diagnosis AFF RVR greater than or equal to 120 bpm
Diltiazem as rate control agent
English speaking

Exclusion

Hemodynamically unstable patients (SBP \<90, MAP \<65)
Impaired consciousness
End stage renal disease on hemodialysis or peritoneal dialysis
Acute heart failure exacerbation based on clinical diagnosis, physician exam, bedside echo, and/or additional imaging
Patient in AFF RVR that is highly suspected to be a compensatory mechanism for an alternative clinical diagnosis
Rhythms other than AF, such as sick sinus syndrome or wide-complex ventricular response
Acute myocardial infarction
Pregnancy defined as a positive urine HCG (human chorionic gonadotropin)
Contraindications to magnesium sulfate (including myasthenia gravis)
Allergy or sensitivity to any study drugs
Previously enrolled in this trial during a different patient encounter
Withdrew from study

What this trial measures

  • Ventricular rate controlWithin the first 2 hours of intravenous magnesium administration

    Assessing ventricular rate control within the first 2 hours of intravenous magnesium administration as defined as a ventricular rate of \< 120 bpm.